Smoking is still the number one preventable cause of death in the U.S. and lung cancer is far and away the number one cause of cancer death in the U.S.
More than 50 cancer organizations to issue a call to action urging individuals, providers, and insurers to increase access to and utilization of low-dose CT scans for those at high risk for lung cancer.
Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.
Stand Up To Cancer formed three teams investigating treatments for Non-Small Cell Lung Cancer and Ewing sarcoma, including a Lung Cancer Health Equity SU2C Catalyst Research Team with support from Bristol Myers Squibb and two SU2C Catalyst Research Teams with support from Jazz Pharmaceuticals.
Through extensive single-cell analysis, researchers at MD Anderson Cancer Center have created a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, highlighting previously unappreciated roles these immune cells play in tumor development and treatment outcomes.
Sexual dysfunction is highly prevalent in women with lung cancer with most survey participants reporting little to no interest in sexual activity, according to research led by Narjust Florez (Duma).
A phase II clinical trial of poziotinib for non-small cell lung cancer with epidermal growth factor receptor exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may impact future clinical trials for EGFR exon 20 targeted therapies.
FDA granted Orphan Drug Designation to stage LSD1 inhibitor iadademstat for the treatment of patients with small cell lung cancer.
Winship Cancer Institute of Emory University was awarded a P01 program project grant from NCI to support research aimed at improving the effectiveness of immunotherapy for lung cancer in patients with a mutation of the LKB1 gene, a group for whom present immunotherapy options do not provide robust benefit.
An analysis conducted by Friends of Cancer Research showed that the FDA Breakthrough Therapy Designation criteria select drugs that lead to better outcomes for patients with lung cancer.
